Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CBX7 | O95931 | 3/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 3/20 | 0.43 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 3/20 | 0.43 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16601597 | 0.82 | HPGD (0.64) | HPGDTP53SMN1; SMN2MAPK1MEN1 | |
| SCHEMBL13340922 | 0.81 | SMN1; SMN2 (0.51) | HPGDTP53POLBMAPTSMN1; SMN2 | |
| SCHEMBL4413144 | 0.79 | HPGD (0.64) | HPGDTP53POLBSMN1; SMN2MAPK1 | |
| SCHEMBL4414360 | 0.79 | HPGD (0.64) | HPGDTP53POLBMAPTMEN1 | |
| SCHEMBL4411794 | 0.79 | HPGD (0.64) | HPGDTP53SMN1; SMN2MAPK1CBX7 | |
| SCHEMBL4413088 | 0.78 | HPGD (0.59) | HPGDTP53POLBSMN1; SMN2CBX7 | |
| SCHEMBL13341138 | 0.78 | POLB (0.44) | TP53POLBMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL13341017 | 0.76 | PPARG (0.46) | TP53POLBMAPTSMN1; SMN2 | |
| SCHEMBL4414345 | 0.75 | HPGD (1.00) | HPGDPOLBMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL16250472 | 0.73 | HPGD (0.64) | HPGDPOLBSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | HPGD 1434/4885TP53 1863/4885POLB 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.